F1-340. Specific Spectrum Activity of AFN-1252 against Bacterial Pathogens Isolated from Patients in Canadian Hospitals: CANWARD 2007
Session: Poster Session: Fatty Acid Biosynthesis and Protein Biosynthesis Inhibitors
Saturday, October 25, 2008: 12:00 AM
Room: Hall C
Background: AFN-1252 (AFN) is a potent inhibitor of enoyl-ACP reductase (FabI) that is being developed as a PO/IV specific spectrum agent for treatment of staphylococcal infections. We determined the in vitro activity of AFN against recent gram-positive (GP) and gram-negative (GN) pathogens isolated from patients in medical and surgical wards, intensive care units, clinics, and emergency rooms at 12 Canadian hospitals from Jan-Dec 2007. Methods: AST was performed using the CLSI broth microdilution method. Results: The activity of AFN versus selected comparators is summarized below.
Organism (n) MIC 50/MIC 90 (ug/ml)
AFN-1252CefazolinCiprofloxacinVancomycin
MSSA (372)≤0.008/≤0.008≤0.5/10.5/81/1
MRSA (130)≤0.008/≤0.00864/>128>16/>161/1
MSSE (43)≤0.008/0.031/44/>161/2
MRSE (9)≤0.008**64**>16**1**
S. pneumoniae (490)>4/>4NA1/2≤0.06/0.5
E. faecalis (81)>4/>432/1282/>161/2
E. faecium (38)>4/>4>128/>128>16/>160.5/>8
E. coli (599)>4/>42/64≤0.06/>16>8/>8
K. pneumoniae (199)>4/>42/8≤0.06/0.5>8/>8
P. aeruginosa (137)>4/>4>128/>1280.5/16>8/>8
*VISA (12)0.015/0.12128/>128>16/>164/4
*VRSA (7)0.015**128**>16**>16**
*Isolates obtained through the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) program: supported under NIAID, NIH Contract No. N01-AI-95359. **Median MIC. Conclusions: AFN-1252 demonstrated potent activity against staphylococci, including MRSA, MRSE, VISA, and VRSA but was inactive against other GP and GN pathogens. These data support the continued development of AFN-1252 for treatment of resistant staphylococcal infections.
Barry Hakfin1, Daryl J. Hoban, PhD2, George G. Zhanel, PhD3, James Karlowsky, PhD4, Nachum Kaplan, PhD5, Nancy Laing4 and  G. G. Zhanel,
Abbott Received: Research Grant.
Affinium Received: Research Grant.
Astellas Received: Research Grant.
Ortho McNeil Received: Research Grant.
Oryx Received: Research Grant.
Pfizer Received: Research Grant., (1)Affinium Pharmaceuticals Inc., (2)Health Sciences Centre, Winnipeg, MB, Canada, (3)Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada, (4)University of Manitoba, Winnipeg, MB, Canada, (5)Affinium Pharmaceuticals, Toronto, ON, Canada


<< Previous Abstract | Next Abstract